Skip to content
2000
Volume 19, Issue 2
  • ISSN: 1871-5230
  • E-ISSN: 1875-614X

Abstract

Progranulin (PGRN) mediates cell cycle progression and cell motility as a pleiotropic growth factor and acts as a universal regulator of cell growth, migration and transformation, cell cycle, wound healing, tumorigenesis, and cytotoxic drug resistance as a secreted glycoprotein. PGRN overexpression can induce the secretion of many inflammatory cytokines, such as IL-8, -6,-10, TNF-α. At the same time, this protein can promote tumor proliferation and the occurrence and development of many related diseases such as gastric cancer, breast cancer, cervical cancer, colorectal cancer, renal injury, neurodegeneration, neuroinflammatory, human atherosclerotic plaque, hepatocarcinoma, acute kidney injury, amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. In short, PGRN plays a very critical role in injury repair and tumorigenesis, it provides a new direction for succeeding research and serves as a target for clinical diagnosis and treatment, thus warranting further investigation. Here, we discuss the potential therapeutic utility and the effect of PGRN on the relationship between inflammation and cancer.

Loading

Article metrics loading...

/content/journals/aiaamc/10.2174/1871523018666190724124214
2020-06-01
2025-09-10
Loading full text...

Full text loading...

/content/journals/aiaamc/10.2174/1871523018666190724124214
Loading

  • Article Type:
    Review Article
Keyword(s): Cell cycle; cell motility; inflammation; pleiotropic growth factor; progranulin; tumor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test